The Global Blood Screening Market is estimated to grow at a CAGR of 9.8% during the forecast period.
On the basis of technology, the market has been classified as nucleic acid amplification test (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, next-generation sequencing (NGS), western blotting.
The nucleic acid amplification test is segmented into transcription-mediated amplification (TMA) and real-time polymerase chain reaction (PCR).
On the basis of products and services, the market has been classified as reagent and kits, enzymes and polymerases, standards and controls, probes and primers, buffers, nucleotides, and solutions, immunosorbents, instruments and software and services.The Americas is projected to lead the blood screening market in the forecast period.
Jul 22, 2019 (AB Digital via COMTEX) -- The Global Blood Screening Market is expected to register a growth of significant CAGR 9.8% during the forecast period (2018–2023).
The global blood screening market has been segmented on the devices, service providers, application, end users.
The nucleic acid amplification test is segmented into transcription-mediated amplification (TMA) and real-time polymerase chain reaction (PCR).
Based on products and services, the blood screening market has been classified as reagent and kits, enzymes and polymerases, standards and controls, probes and primers, buffers, nucleotides, and solutions, immunosorbents, instruments and software and services.
U.S. blood screening market dominated industry in 2017, due to the high demand for quality healthcare, vastly developed healthcare infrastructure as well as growing occurrence of cardiac disease in the region.
Frequencies of blood screening are dramatically increasing over the last few years.